GenVec, Inc. (GNVC)
-NasdaqCM 0.72 
0.02(2.84%) 3:57PM EDT
| Prev Close: | 0.70 |
|---|
| Open: | 0.70 |
|---|
| Bid: | 0.00 x 1000 |
|---|
| Ask: | 0.74 x 1200 |
|---|
| 1y Target Est: | 1.80 |
|---|
| Beta: | 1.8 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.69 - 0.73 |
|---|
| 52wk Range: | 0.63 - 2.78 |
|---|
| Volume: | 25,589 |
|---|
| Avg Vol (3m): | 67,230 |
|---|
| Market Cap: | 9.32M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.08 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- GENVEC INC FinancialsEDGAR Online Financials(Tue, May 21)
- GENVEC INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- GENVEC INC Files SEC form 8-K, Other EventsEDGAR Online(Fri, Apr 26)
- UK scientists develop safer foot-and-mouth vaccineat Reuters(Wed, Mar 27)
- GenVec Q4 Net Loss Deepensat Motley Fool(Fri, Mar 22)
- GenVec CEO Discusses Q4 2012 Results - Earnings Call Transcriptat Seeking Alpha(Fri, Mar 22)
- GenVec, Inc. Earnings Call scheduled for 10:00 am ET todayCCBN(Fri, Mar 22)
- GenVec sees FY13 cash burn to be between $8M-$9Mtheflyonthewall.com(Fri, Mar 22)
- GenVec Reports Fourth Quarter And 2012 Year-End Financial ResultsPR Newswire(Fri, Mar 22)
- Q4 2012 GenVec, Inc. Earnings Release - Before Market OpenCCBN(Fri, Mar 22)
- GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Fri, Mar 22)
- Companies reporting Before the Market Open on Friday, March 22at theflyonthewall.com(Thu, Mar 21)
- Companies reporting Before the Market Open on Friday, March 22theflyonthewall.com(Thu, Mar 21)
- GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013PR Newswire(Fri, Mar 15)
- GenVec to Present at 25th Annual ROTH ConferencePR Newswire(Tue, Mar 12)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 1.23 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.63 |
|---|
| Quarterly EPS Est
(Mar-13)
: | -0.13 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | -0.03 |
|---|
Business Summary
GenVec, Inc. operates as a biopharmaceutical company that uses differentiated and proprietary technologies to create therapeutics and vaccines. The company develops and commercializes its product candidates through collaborations with various comp...
View More